What Did US FDA Do Wrong In Its Review Of Aducanumab? AdCom Members Have A List

 
• By Brenda Sandburg
  
Abstract mash line and point Question mark. Business illustration. Polygonal low poly
FDA Advisory Committee has many questions about aducanumab Alzheimer's disease drug • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers